Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 27;15(1):18.
doi: 10.1186/s12916-017-0781-0.

Respiratory Effect of Beta-Blockers in People With Asthma and Cardiovascular Disease: Population-Based Nested Case Control Study

Affiliations
Free PMC article

Respiratory Effect of Beta-Blockers in People With Asthma and Cardiovascular Disease: Population-Based Nested Case Control Study

Daniel R Morales et al. BMC Med. .
Free PMC article

Abstract

Background: Cardiovascular disease (CVD) is a common comorbidity in people with asthma. However, safety concerns have caused heterogeneity in clinical guideline recommendations over the use of cardioselective beta-blockers in people with asthma and CVD, partly because risk in the general population has been poorly quantified. The aim of this study was to measure the risk of asthma exacerbations with beta-blockers prescribed to a general population with asthma and CVD.

Methods: Linked data from the UK Clinical Practice Research Datalink was used to perform nested case-control studies among people with asthma and CVD matched on age, sex and calendar time. Adjusted incidence rate ratios (IRR) were calculated for the association between oral beta-blocker use and moderate asthma exacerbations (rescue oral steroids) or severe asthma exacerbations (hospitalisation or death) using conditional logistic regression.

Results: The cohort consisted of 35,502 people identified with active asthma and CVD, of which 14.1% and 1.2% were prescribed cardioselective and non-selective beta-blockers, respectively, during follow-up. Cardioselective beta-blocker use was not associated with a significantly increased risk of moderate or severe asthma exacerbations. Consistent results were obtained following sensitivity analyses and a self-controlled case series approach. In contrast, non-selective beta-blockers were associated with a significantly increased risk of moderate asthma exacerbations when initiated at low to moderate doses (IRR 5.16, 95% CI 1.83-14.54, P = 0.002), and both moderate and severe exacerbations when prescribed chronically at high dose (IRR 2.68, 95% CI 1.08-6.64, P = 0.033 and IRR 12.11, 95% CI 1.02-144.11, P = 0.048, respectively).

Conclusions: Cardioselective beta-blockers prescribed to people with asthma and CVD were not associated with a significantly increased risk of moderate or severe asthma exacerbations and potentially could be used more widely when strongly indicated.

Keywords: Asthma; Beta-blocker; Cardiovascular disease; Drug safety; Pharmacovigilance.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Steppuhn H, Langen U, Keil T, et al. Chronic disease co-morbidity of asthma and unscheduled asthma care among adults: results of the national telephone health interview survey German Health Update (GEDA) 2009 and 2010. Prim Care Respir J. 2014;23:22–9. doi: 10.4104/pcrj.2013.00107. - DOI - PMC - PubMed
    1. Hamer J, Grandjean T, Melendez L, et al. Effect of propranolol (inderal) in angina pectoris: preliminary report. Br Med J. 1964;2(5411):720–3. doi: 10.1136/bmj.2.5411.720. - DOI - PMC - PubMed
    1. Prichard BN, Gillam PM. Use of propranolol (inderal) in treatment of hypertension. Br Med J. 1964;2(5411):725–7. doi: 10.1136/bmj.2.5411.725. - DOI - PMC - PubMed
    1. McNeill RS, Ingram CG. Effect of propranolol on ventilatory function. Am J Cardiol. 1966;18:473–5. doi: 10.1016/0002-9149(66)90072-5. - DOI - PubMed
    1. Morales DR, Guthrie B, Lipworth BJ, et al. Prescribing of β-adrenoceptor antagonists in asthma: an observational study. Thorax. 2011;66:502–7. doi: 10.1136/thoraxjnl-2011-200067. - DOI - PubMed

Substances

Feedback